Sino Biopharmaceutical Limited
1177
Κατάταξη σε μετοχές
#1770
Sino Biopharmaceutical Limited, an investment holding company, operates as a... Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Τιμή μετοχής
$0.68248644
Κεφαλαιοποίηση
$12.15B
Αλλαγή (1 ημέρα)
-1.20%
Αλλαγή (1 έτος)
-28.32%
Χώρα
HK
Εμπόριο Sino Biopharmaceutical Limited (1177)
Κατηγορία
Healthcare
Κέρδη για την Sino Biopharmaceutical Limited (1177)
Κέρδη τον Jun 2026 TTM: $1.21B
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Sino Biopharmaceutical Limited, τα τρέχοντα κέρδη της εταιρείας είναι $1.21B. Το 2023, η εταιρεία παρουσίασε κέρδη $764.26M, αύξηση σε σχέση με των κερδών του 2022 που ήταν $756.01M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Sino Biopharmaceutical Limited από 2000 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $1.21B | 66.67% |
| 2024 | $723.03M | -5.40% |
| 2023 | $764.26M | 1.09% |
| 2022 | $756.01M | -74.13% |
| 2021 | $2.92B | 280.79% |
| 2020 | $767.38M | -4.30% |
| 2019 | $801.89M | -51.74% |
| 2018 | $1.66B | 157.64% |
| 2017 | $644.90M | 33.59% |
| 2016 | $482.76M | 8.71% |
| 2015 | $444.09M | 22.80% |
| 2014 | $361.64M | 31.39% |
| 2013 | $275.23M | 19.15% |
| 2012 | $231.00M | 80.70% |
| 2011 | $127.84M | -8.96% |
| 2010 | $140.42M | 36.19% |
| 2009 | $103.10M | 33.11% |
| 2008 | $77.46M | 76.36% |
| 2007 | $43.92M | 66.73% |
| 2006 | $26.34M | 81.55% |
| 2005 | $14.51M | -64.22% |
| 2004 | $40.55M | 81.70% |
| 2003 | $22.32M | 28.38% |
| 2002 | $17.38M | 15.22% |
| 2001 | $15.09M | 37.33% |
| 2000 | $10.99M | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| $1.35B | 12.01% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $26.37M | -97.81% |
US
|
